DYNACIRC
LOE ApproachingNDAORALCAPSULE
Approved
Dec 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DYNACIRC is an oral capsule small-molecule NDA approved by GSK in December 1990. The specific mechanism of action and therapeutic indication are not disclosed in available data, limiting clinical characterization.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30 score), signaling a transitional team focused on generics defense and brand loyalty rather than growth investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect LOE-stage status with minimal hiring activity. Career progression on DYNACIRC is limited; professionals should anticipate transition to emerging GSK portfolios or defensive brand roles managing generics erosion.
Brand ManagerField Sales Representative
Worked on DYNACIRC at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.